Get the Stockscreener App
83.88
0.77%
-0.65
After Hours:
83.88
Dexcom Inc stock is traded at $83.88, with a volume of 3.95M.
It is down -0.77% in the last 24 hours and down -1.03% over the past month.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.
See More
Previous Close:
$84.53
Open:
$83.93
24h Volume:
3.95M
Relative Volume:
0.82
Market Cap:
$31.65B
Revenue:
$4.82B
Net Income/Loss:
$930.40M
P/E Ratio:
35.88
EPS:
2.3381
Net Cash Flow:
$1.43B
1W Performance:
-6.48%
1M Performance:
-1.03%
6M Performance:
+22.03%
1Y Performance:
+6.99%
1-Day Range:
$82.80
$85.16
1-Week Range:
$82.80
$91.00
52-Week Range:
$54.11
$92.59
Dexcom Inc Stock (DXCM) Company Profile
Name
Dexcom Inc
Sector
Industry
Phone
(858) 200-0200
Address
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Compare DXCM vs ABT, MDT, SYK, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
83.88 | 31.90B | 4.82B | 930.40M | 1.43B | 2.3381 |
ABT
Abbott Laboratories
|
105.23 | 182.59B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
91.89 | 118.18B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
275.39 | 106.03B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
44.96 | 65.19B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.18 | 49.99B | 6.30B | 1.07B | 1.09B | 1.8406 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-24-26 | Upgrade | Evercore ISI | In-line → Outperform |
| Jan-12-26 | Downgrade | Barclays | Equal Weight → Underweight |
| Dec-02-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-25-25 | Initiated | Evercore ISI | In-line |
| Oct-21-25 | Resumed | Stifel | Buy |
| Sep-08-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-21-25 | Initiated | Argus | Buy |
| Jun-16-25 | Initiated | Truist | Buy |
| May-30-25 | Initiated | Goldman | Buy |
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Feb-03-25 | Upgrade | Redburn Atlantic | Neutral → Buy |
| Jan-16-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jul-26-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-26-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-30-24 | Initiated | Redburn Atlantic | Neutral |
| Mar-12-24 | Initiated | RBC Capital Mkts | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| Apr-17-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-29-23 | Initiated | UBS | Buy |
| Jan-26-23 | Initiated | Wolfe Research | Outperform |
| Oct-18-22 | Initiated | Barclays | Equal Weight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-15-22 | Initiated | Bernstein | Outperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Feb-03-22 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-19-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-07-22 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-18-21 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-21-21 | Resumed | Cowen | Outperform |
| May-28-21 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Overweight |
| Jan-06-21 | Upgrade | UBS | Neutral → Buy |
| Oct-02-20 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| May-27-20 | Reiterated | Piper Sandler | Overweight |
| May-14-20 | Initiated | Wells Fargo | Equal Weight |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Nov-07-19 | Reiterated | Canaccord Genuity | Buy |
| Nov-07-19 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-23-19 | Initiated | Stifel | Buy |
| Nov-28-18 | Initiated | UBS | Neutral |
| Oct-19-18 | Upgrade | Goldman | Sell → Neutral |
| Sep-12-18 | Upgrade | Northland Capital | Under Perform → Market Perform |
| Aug-02-18 | Reiterated | Canaccord Genuity | Buy |
| Jul-02-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-08-18 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-18 | Initiated | BofA/Merrill | Buy |
| May-03-18 | Reiterated | Canaccord Genuity | Buy |
| Apr-04-18 | Initiated | Goldman | Sell |
| Apr-04-18 | Initiated | Guggenheim | Neutral |
| Mar-23-18 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jan-04-18 | Downgrade | Northland Capital | Market Perform → Under Perform |
| Sep-28-17 | Reiterated | Wedbush | Outperform |
View All
Dexcom Inc Stock (DXCM) Latest News
Dexcom Inc. stock steadies near mid-range as conference outlines growth plan - ad-hoc-news.de
DexCom expects CONNECT study on type 2 diabetes to be published soon in a major journal. - Pluang
Dexcom at Wells Fargo conference: coverage push drives growth plan By Investing.com - Investing.com India
Transcript : DexCom, Inc. Presents at Wells Fargo 21st Annual Healthcare Conference, Sep-09-2026 08:00 AM - marketscreener.com
Dexcom stock heads into the open after a 3.8 percent drop - ad-hoc-news.de
Kakao Healthcare Lends Glucose Monitors to Diabetic Exam Takers - Seoul Economic Daily
DexCom Inc (DXCM) Shares Fall 3.8% -- What GF Score of 95 Tells Investors - GuruFocus
DexCom Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
DexCom Stock: Is DXCM Underperforming the Healthcare Sector? - finance.yahoo.com
Law firm probes DexCom officers for possible br... - Pluang
Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - PR Newswire
Dexcom Inc. stock holds near consensus target on solid Q2 2026 growth - ad-hoc-news.de
Dexcom stock holds near USD 89.71 after strong Q2 - AD HOC NEWS
DexCom (DXCM) Stock Looks Undervalued On Fair Value While Earnings Look Fair - finance.yahoo.com
Q2 Earnings Highs And Lows: DexCom (NASDAQ:DXCM) Vs The Rest Of The Patient Monitoring Stocks - finance.yahoo.com
Revisiting Stock Picks Dexcom, Bristol Myers Squibb, Quanta Services - Barron's
ETFs Investing in DexCom, Inc. Stocks - TradingView
Why DexCom (DXCM) is a Top Growth Stock for the Long-Term - Eastern Progress
DexCom Inc. stock outperforms competitors despite losses on the day - MarketWatch
3 Reasons DXCM Has Explosive Upside Potential - Yahoo Finance
Here's How Much a $1000 Investment in DexCom Made 10 Years Ago Would Be Worth Today - qz.com
Dexcom Announces Upcoming Conference Presentation - Business Wire
G7 Momentum and Global Reach Might Change The Case For Investing In DexCom (DXCM) - simplywall.st
DexCom, Inc. (DXCM) Stock Analysis: Strong Buy Ratings And A Promising 3.63% Upside - directorstalkinterviews.com
Dexcom (DXCM) HR chief cashes out 2,565 company shares - stocktitan.net
Dexcom Defeats Investor Suit Over Glucose Monitor Market Share - Bloomberg Law News
FDA Approves Abbott's First Wearable Device for Dual Ketone and Glucose Tracking - Sahm
Dexcom, Abbott await Medicare coverage expansion for CGMs - MedTech Dive
We Ran A Stock Scan For Earnings Growth And DexCom (NASDAQ:DXCM) Passed With Ease - Moomoo
Dexcom (NASDAQ: DXCM) officer keeps 101,502 shares after tax withholding - Stock Titan
Abbott vs. DexCom: Which CGM Stock Is the Better Buy Now? - Eastern Progress
Dexcom (NASDAQ: DXCM) CEO retains 418,908 shares after tax withholding - Stock Titan
Dexcom (NASDAQ: DXCM) chair sells 26,756 shares around $90 - Stock Titan
DexCom, Inc. (DXCM) Investor Outlook: Navigating the Healthcare Sector with Promising Growth Potential - directorstalkinterviews.com
Bronstein, Gewirtz & Grossman, LLC Encourages DexCom, Inc. (DXCM) - The National Law Review
DexCom (NASDAQ:DXCM) Reaches New 52-Week HighStill a Buy? - MarketBeat
DexCom stock hits 52-week high at 91.99 USD - Investing.com
DexCom Study Demonstrates CGM Benefits in Type 2 Diabetes - Medical Product Outsourcing
DXCM Shareholders Have Opportunity to Lead DexCom, Inc. Class Act - The National Law Review
DexCom posts $1.31B quarter as Silvant Capital opens a $5.4M stake - Dealroom
Silvant Capital Management LLC Takes $5.36 Million Position in DexCom, Inc. $DXCM - MarketBeat
Trillium Asset Management LLC Invests $3.23 Million in DexCom, Inc. $DXCM - MarketBeat
Danske Bank A S Purchases New Holdings in DexCom, Inc. $DXCM - MarketBeat
DexCom Inc. stock outperforms competitors on strong trading day - MarketWatch
Dexcom (NASDAQ:DXCM) Combines Strong Growth With a Bullish Technical Setup - ChartMill
Dexcom stock holds close to analyst target as growth story stays intact - Ad-hoc-news.de
E Fund Management Co. Ltd. Acquires New Holdings in DexCom, Inc. $DXCM - MarketBeat
Edmond DE Rothschild Holding S.A. Invests $5.01 Million in DexCom, Inc. $DXCM - MarketBeat
Deutsche Bank AG Takes Position in DexCom, Inc. $DXCM - MarketBeat
Aurora Investment Counsel Invests $2.34 Million in DexCom, Inc. $DXCM - MarketBeat
Dexcom (NASDAQ: DXCM) Kevin R. Sayer plans multimillion-dollar stock sale - Stock Titan
Dexcom Inc Stock (DXCM) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.40%
0.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):